Interferon effects on herpes simplex virus in rabbit and human cell cultures

Effects of human recombinant alpha-2b interferon and feline recombinant omega interferon on in vitro replication of feline herpesvirus-1

OBJECTIVE

To evaluate the effects of recombinant human interferon alpha-2b (rHuIFN-alpha2b) and recombinant feline interferon omega (rFeIFN-omega) on in vitro replication of feline herpesvirus (FHV)-1.

SAMPLE POPULATION

Cultures of Crandell-Rees feline kidney (CRFK) cells.

PROCEDURES

CRFK cells were treated with rFeIFN-omega or rHuIFN-alpha2b at concentrations ranging from 100 to 500,000 U/mL. Cultures were then inoculated with FHV-1. Constant concentrations of interferon products were maintained throughout the study. Reductions in the number and size of plaques were used as indicators of antiviral activity. Six plaque reduction assays were performed in duplicate. A 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay was used to detect cytotoxic effects of interferon. A 1-way ANOVA and Dunnett test were used to determine significant differences.

RESULTS

Treatment with rFeIFN-omega at various concentrations resulted in significant reductions in the number of plaques (100,000 U/mL, 54.7%; and 500,000 U/mL, 59.8%) and in plaque size (100,000 U/mL, 47.5%; 250,000 U/mL, 81.0%; and 500,000 U/mL; 70.5%). Treatment with various concentrations of rHuIFN-alpha2b resulted in a significant reduction in plaque size (100,000 U/mL, 56.0%; 250,000 U/mL, 75.7%; and 500,000 U/mL, 69.0%). None of the tested concentrations of interferon caused significant cellular toxicosis.

CONCLUSIONS AND CLINICAL RELEVANCE

At some of the higher concentrations, the antiviral effect of rFeIFN-omega was greater than the antiviral effect of rHuIFN-alpha2b. Reduction in plaque size appeared to be a good indicator of the antiviral activity of interferon against FHV-1.

The comparative anti-herpes simplex virus effects of human interferons

The mechanism(s) of anti-herpes simplex virus (HSV) activity of interferons (IFNs) have not been clearly identified. We have tested natural and recombinant human IFN-alpha, IFN-beta, and IFN-gamma preparations for their relative anti-HSV activity in human corneal and Vero monkey kidney cells. The relative anti-HSV activities in corneal cells were IFN-beta > rIFN-gamma > IFN-alpha (lymphoblastoid) > rIFN-beta2a = rIFN-alphaA/D. IFN-beta at 100 IU/ml reduced virus yield by 59+/-24%. The relative anti-HSV activity in Vero cells was rIFN-gamma > IFN-beta = IFN-alpha (lymphoblastoid) > rIFN-alphaA/D > rIFN-alpha2a. IFN-gamma at 100 IU/ml reduced virus yields by 90+/-4%. Reducing the multiplicity of infection significantly increased the apparent antiviral activity of all IFNs. The antiviral activity of IFNs could be detected by 4 h after treatment of Vero cells but not until 8 h in corneal cells. Western blot analysis showed that none of the IFNs detectably reduced the levels of immediate-early HSV protein, ICP4, but some reduced ICP0 levels early during infection, the extent and duration of the reduction varying with both IFN and cell type. The greatest effects on viral protein levels were detected in IFN-y-treated Vero cells. These data indicated that the targets of the anti-HSV activities of IFNs can vary with both IFN and cell type.